Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. - Wikidata - awgldk - TriplyDB

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

http://www.wikidata.org/entity/Q35107668

about

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.

P2860

Q26740253-8EADFFBB-91E7-4906-A6B9-B4040FA7F5D4 Q38783203-379D95DB-37AF-4699-A7A8-CD29CFA7465F Q44020766-E21D8D6F-D9D8-49FD-AEA5-F95794CDE0A9

P2860

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

http://www.wikidata.org/entity/Q35107668

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@ast

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@en

type

label

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@ast

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@en

prefLabel

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@ast

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@en

P1433

Q35107668-BE183D82-A585-4C5B-8241-3C262584F38B

P1476

Q35107668-74034419-7B9D-40AF-BDB7-B7B8DD3EC0F9

P2093

Q35107668-0C026F2A-9D6E-4AE8-9752-83B1BCA41149

Q35107668-2D410A1D-10E6-4460-9D1F-49A4DC16D100

Q35107668-9ABFC25E-9622-477B-A35A-CF7472D3C40A

P2860

Q35107668-01DB3986-FD65-4BEF-AAB5-A71D2BE59C33

Q35107668-0254C33F-B18C-4C37-8720-838265EEB096

Q35107668-0284D6C4-8B7A-4B3D-A35C-D67A89117DAC

Q35107668-02ABA89B-9AEB-464C-9EDE-576CC1EEAE2A

Q35107668-0969818E-403A-4535-B317-D7870A5BBBF5

Q35107668-14D8B7A7-97EB-44BB-97E1-437A12127C3E

Q35107668-1600474A-9ABF-40C5-9805-CDF8F8921CD5

Q35107668-17835E43-E541-4CF5-94D8-C0C392B3EF3B

Q35107668-17C1549A-69AD-44F9-AA52-2C1772EFFD6D

Q35107668-19DB12E0-75CB-48DC-8306-5F8FC21C4450

P304

Q35107668-8E7252C0-425A-4649-ABD6-C221E0AE155D

P31

Q35107668-0B43A132-589E-42C3-978A-6EF08F388518

P356

Q35107668-10468E0B-EEE3-432C-8244-E366443F29F5

P478

Q35107668-790C8F0F-A75F-42E4-8DBE-56D80AD2776B

P50

Q35107668-471DB6A3-268F-4DBD-846F-6532DF70BB67

P577

Q35107668-98ED45CF-B8B9-49A5-AEED-EB0FFEE6A749

P5875

Q35107668-2333F2F2-C551-45CA-AB4A-2BF4EDBB3210

P698

Q35107668-98187631-7BE9-4DCE-B0A0-B2F1CAA5FEFA

P921

Q35107668-84C18A66-060D-48E6-A424-741DDC8A9120

P932

Q35107668-794B3314-BB7E-4E99-8F70-3A381FA4A121

P356

1874192401105010085

P1433

Open Cardiovascular Medicine Journal

P1476

Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

@en

P2093

Asterios Karagiannis

http://www.w3.org/2001/XMLSchema#string

Konstantinos Tziomalos

http://www.w3.org/2001/XMLSchema#string

Vasilios G Athyros

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study.

P304

85-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1874192401105010085

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Dimitri P Mikhailidis

P577

2011-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51502362

http://www.w3.org/2001/XMLSchema#string

P698

21769302

http://www.w3.org/2001/XMLSchema#string

P921

P932

3137137

http://www.w3.org/2001/XMLSchema#string